As far as I know, none of the stock brokers allowed for success of CSL112 in their price targets. Any reaction to this trial failing will be short lived. The SP will be governed by the financial results and most importantly outlook statement. If they upgrade guidance, the SP is sure to go higher from here. If guidance is maintained, there is no reason for the SP to fall back to the low to mid 200s.
One needs to keep in mind that the fall to mid $200s was not solely due to company performance. The rising interest rates played a big part in that.
Ann: Top-line Results from the Phase 3 AEGIS-II Trial, page-17
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$300.58 |
Change
-1.210(0.40%) |
Mkt cap ! $145.5B | |||
| Open | High | Low | Value | Volume |
| $300.74 | $300.99 | $298.81 | $240.1M | 820.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $300.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $300.59 | 836 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| CSL (ASX) Chart |